Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. As the U.S. market experiences heightened volatility ...

In this article, we are going to take a look at where Akebia Therapeutics, Inc. (NASDAQ:AKBA) stands against other stocks to ...

The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by HC Wainwright ... The last upgrade for Akebia Therapeutics Inc happened on August 28, 2023 when HC Wainwright ...

One stock that might be an intriguing choice for investors right now is Akebia Therapeutics, Inc. AKBA. This is because this security in the Medical - Drugs space is seeing solid earnings estimate ...

The firm increased its portfolio allocation in AKBA by 41.87% over the last quarter. Geode Capital Management holds 4,795K shares representing 2.03% ownership of the company. In its prior filing ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $6.00. The company’s shares ...

AKEBIA THERAPEUTICS ($AKBA) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.10 per share, missing estimates of -$0.08 ...

Charles Schwab Investment Management Inc. raised its stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Free Report) by 3.2% during the fourth quarter, HoldingsChannel reports.